Precision Therapeutics Raises $43 Million
November 11, 2008
Precision Therapeutics has secured $43 million in additional funding to expand the development and commercialization of ChemoFX, a diagnostic test that helps physicians select the most effective chemotherapeutic regiment for cancer patients. The round was led by Longitude Venture Partners, and included existing investors Draper Triangle, Adams Capital Management, Quaker BioVentures, Birchmere Ventures, and Techno Venture Management. The capital infusion will allow the company to expand its market penetration and pursue new programs concerning individualized therapy for cancer patients. The company has raised $105 million in VC funds in the last 10 years. Learn more at www.precisiontherapeutics.com.
« BFTP Announces $100,000 Big Idea Contest | | Carnegie Learning Curricula Preferred Learning Resource in KY Through 2015 »
